Management ChangeJul 9, 2026, 05:16 PM
Travere Therapeutics CAO Sandra Calvin to Retire; John Torell to Succeed
AI Summary
Travere Therapeutics, Inc. announced that Sandra Calvin, its Chief Accounting Officer and Principal Accounting Officer, will retire from the company following the filing of the Annual Report on Form 10-K, expected in February 2027. John Torell, the current Vice President, Controller, is expected to succeed Ms. Calvin in these roles. The Board of Directors plans to appoint Mr. Torell prior to the retirement date to ensure an orderly transition of responsibilities.
Key Highlights
- Sandra Calvin, Chief Accounting Officer, to retire from Travere Therapeutics.
- Retirement expected after the filing of the Annual Report on Form 10-K in February 2027.
- John Torell, current VP, Controller, expected to succeed Ms. Calvin as CAO and PAO.
- Board of Directors expected to appoint Mr. Torell before the retirement date for transition.
- Mr. Torell joined the Company in 2021 and has been VP, Controller since 2023.
- Mr. Torell is a Chartered Financial Analyst (CFA) and Certified Public Accountant (CPA).
Price Impact
More from TVTX